{"denoms":[{"counts":[{"groupId":"BG000","value":"8"}],"units":"Participants"}],"groups":[{"description":"INDUCTION (COURSES 1-4): Patients receive ixazomib citrate PO on days 1, 8, and 15, pomalidomide PO on days 1-21, and dexamethasone PO on days 1, 8, 15, and 22. Treatment repeats every 28 days (courses 1-3) and 56 days (course 4) for up to 4 courses in the absence of disease progression or unacceptable toxicity.\\> \\> TRANSPLANTATION (COURSE 5): Between 2-4 weeks following Induction, patients undergo ASCT.\\>\n\n\\> CONSOLIDATION (COURSES 6-9): Beginning 60-120 days following ASCT, patients receive ixazomib citrate, pomalidomide, and dexamethasone as in Induction. Treatment repeats every 28 days (courses 6-8) and 56 days (course 9) for up to 4 courses in the absence of disease progression or unacceptable toxicity.\\>\n\n\\> MAINTENANCE (COURSES 10+): Beginning 0-4 weeks following Consolidation, patients receive ixazomib citrate as in Induction. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.\\>\n\n\\> Autologous Hematopoietic Stem Cell Transplantation: Undergo ASCT\\>\n\n\\> Dexamethasone: Given PO\\>\n\n\\> Ixazomib Citrate: Given PO\\>\n\n\\> Laboratory Biomarker Analysis: Correlative studies\\>\n\n\\> Pomalidomide: Given PO","id":"BG000","title":"Treatment (Ixazomib, Pomalidomide, Dexamethasone, ASCT)"}],"measures":[{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","spread":"11.17","value":"63.5"}]}]}],"dispersionType":"STANDARD_DEVIATION","paramType":"MEAN","title":"Age, Continuous","unitOfMeasure":"years"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"1"}],"title":"Female"},{"measurements":[{"groupId":"BG000","value":"7"}],"title":"Male"}]}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Sex: Female, Male","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"2"}],"title":"Hispanic or Latino"},{"measurements":[{"groupId":"BG000","value":"6"}],"title":"Not Hispanic or Latino"},{"measurements":[{"groupId":"BG000","value":"0"}],"title":"Unknown or Not Reported"}]}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Ethnicity (NIH/OMB)","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"0"}],"title":"American Indian or Alaska Native"},{"measurements":[{"groupId":"BG000","value":"0"}],"title":"Asian"},{"measurements":[{"groupId":"BG000","value":"0"}],"title":"Native Hawaiian or Other Pacific Islander"},{"measurements":[{"groupId":"BG000","value":"0"}],"title":"Black or African American"},{"measurements":[{"groupId":"BG000","value":"8"}],"title":"White"},{"measurements":[{"groupId":"BG000","value":"0"}],"title":"More than one race"},{"measurements":[{"groupId":"BG000","value":"0"}],"title":"Unknown or Not Reported"}]}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Race (NIH/OMB)","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"8"}]}],"title":"United States"}],"paramType":"NUMBER","title":"Region of Enrollment","unitOfMeasure":"participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"2"}],"title":"Stage I"},{"measurements":[{"groupId":"BG000","value":"5"}],"title":"Stage II"},{"measurements":[{"groupId":"BG000","value":"1"}],"title":"Unknown"}]}],"description":"Stage I (All criteria must be met) - Serum β2 microglobulin\\<3.5 mg/L; Serum albumin≥3.5 g/dL; Del(17p) and/or t(4;14) and/or t(14;16)=No; Abnormal LDH level=No\n\nStage II - All other possible combinations (not Stage I or Stage III)\n\nStage III (All criteria must be met) - Serum β2 microglobulin\\>5.5 mg/L; Serum albumin=NA; Del(17p) and/or t(4;14) and/or t(14;16)=Yes AND/OR Abnormal LDH level=Yes\n\nThe higher the stage, the worse the prognosis.","paramType":"COUNT_OF_PARTICIPANTS","title":"Revised international staging system (R-ISS) myeloma stage at initial diagnosis","unitOfMeasure":"Participants"}]}